## Altered Neuronal and Astroglial Metabolism in APP-PS1 Mouse Model of Alzheimer's Disease

Vivek Tiwari<sup>1</sup>, Pandichelvam Veeraiah<sup>1</sup>, and Anant Bahadur Patel<sup>1</sup>

<sup>1</sup>NMR Microimaging and Spectroscopy, Centre for Cellular and Molecular Biology, Hyderabad, Andhra Pradesh, India

**INTRODUCTION:** Alzheimer's disease (AD) is associated with memory impairment and progressive loss of cognitive functions due to synaptic dysfunction and neuronal loss<sup>1</sup>. We hypothesized that glutamatergic and GABAergic TCA cycle and neurotransmitter cycling will be impaired in AD. As substrate cycle, Glutamate-Glutamine and GABA-Glutamine are result of co-ordinated activity of neurons and astroglia, AD will also affect astroglial activity. APP-PS1 mice, a model of AD, exhibit enormous plaque loading and memory impairment at the age of 12 months- pathology similar to human AD. In this study, we have investigated glutamatergic, GABAergic and astroglial metabolism and corresponding neurotransmitter cycling in cerebral cortex and striatum of APP-PS1 mice brain at 12 months age by <sup>1</sup>H-[<sup>13</sup>C]-NMR spectroscopy together with infusion of <sup>13</sup>C labeled substrates.

**MATERIALS AND METHODS:** All animal experiments were performed under approved protocols by the Institute Animal Ethics Committee. Measurements have been carried out in 12 months old APP-PS1 and age matched control mice. *In vivo* <sup>1</sup>H NMR spectroscopy was carried out in cortical and striatal regions using 600 MHz NMR microimager (Bruker

Avance). For metabolic study, overnight fasted mice were anesthetized with urethane (1.5 g/kg) and tail vein was cannulated for the infusion of <sup>13</sup>C labeled substrates. Mice were infused with either [1,6-<sup>13</sup>C<sub>2</sub>]glucose for 10 min or [2-<sup>13</sup>C]acetate for ~15 min as a bolus-variable rate infusion<sup>2</sup>. Brain was frozen *in situ* in liquid nitrogen at the end of the infusion. Metabolites were extracted from frozen brain tissue<sup>3</sup>. Concentrations and percent <sup>13</sup>C enrichment of metabolites were determined from the <sup>1</sup>H-[<sup>13</sup>C]-NMR spectrum of the cortical extract obtained at 600 MHz spectrometer<sup>4</sup>. The percentage <sup>13</sup>C enrichment of plasma glucose-C1 and acetate-C2 was measured using resonance at 5.2 ppm and 1.93 ppm, respectively in <sup>1</sup>H NMR spectrum.

RESULTS AND DISCUSSIONS: In vivo 1H NMR spectra depicts reduced signal intensity for NAA and Glu in APP-PS1 mouse brain [Fig.1]. This together with increased level of inositol and choline indicates gliosis and impaired neuronal viability in 12 months old APP-PS1 mice. <sup>13</sup>C Labeling of cortical GluC4 and GABAC2 from [1,6-<sup>13</sup>C<sub>2</sub>Iglucose in APP-PS1 mice was found to be lower than age matched control indicating impaired glutamatergic and **GABAergic** metabolism in 12 months old AD mice [Fig. 2A]. However, increased (F[1,9]=12.7, p<0.01) labeling of Gln<sub>C4</sub> (APP-PS1: 0.36±0.04 µmol/g, Control: 0.28±0.03 µmol/g) from [2-13C]acetate indicates higher Glial metabolism in APP-PS1 mice [Fig. 2B]. These findings are in very much consistence with findings of neuro-degeneration and gliosis in AD patients<sup>5,6</sup>.




Fig.2 <sup>13</sup>C Labeling of cortical amino acids from (A) [1,6-<sup>13</sup>C<sub>2</sub>]glucose and (B) [2-<sup>13</sup>C]acetate, \*\*p<0.01

**REFERENCES**: 1.Hardy J *et al* (2002) *Science*,297:353; 2. Fitzpatrick et al (1990) J *Cereb Blood Flow Metab* **10**:170; 3. Patel et al (2004) *Brain Res* **919**:207; 4. de Graaf et al (2003) *Magn Reson Med* **49**:37; 5. Hugg et al (1996) *Ann Neurol* **40**:236; 6. Danielsen et al (1999) *M. Dekker, New York* 

ACKNOWLEDGEMENTS: This study was supported by funding from Department of Biotechnology, India.